A 12-week clinical trial of talsaclidine, a muscarinic agonist, in the treatment of mild to moderate Alzheimer's disease

被引：0
|
作者：
Jones, R
Raschig, A
Müller, A
Müller, S
Ingelheim, B
机构：
[1] Res Inst Care Elderly, Bath, Somerset, England
[2] Boehringer Ingelheim Pharma KG, Biberach, Germany
来源：
NEUROBIOLOGY OF AGING | 2002年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
462
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of donepezil in a 12-week, open-label trial in African Americans with mild to moderate Alzheimer's disease
    Griffith, P
    Lichtenberg, P
    Goldman, R
    Payne-Parrish, J
    Richardson, S
    NEUROLOGY, 2005, 64 (06) : A366 - A366
  • [2] WAL 2014 FU (Talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease
    Ensinger, HA
    Bechtel, WD
    Birke, FW
    Mendla, KD
    Mierau, J
    Speck, G
    Troger, W
    DRUG DEVELOPMENT RESEARCH, 1997, 40 (02) : 144 - 157
  • [3] Safety and efficacy of donepezil in African Americans with mild to moderate Alzheimer's disease: A 12-week open-label trial.
    Griffith, P
    Lichtenberg, P
    Goldman, R
    Payne-Parrish, J
    Richardson, S
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S76 - S76
  • [4] A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease
    Wilkinson, DG
    Passmore, AP
    Bullock, R
    Hopker, SW
    Smith, R
    Potocnik, FCV
    Maud, CM
    Engelbrecht, I
    Hock, C
    Ieni, JR
    Bahra, RS
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (06) : 441 - 446
  • [5] Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: A 12-week randomized double-blind placebo-controlled clinical trial
    Tajadini, Haleh
    Saifadini, Rostam
    Choopani, Rasool
    Mehrabani, Mitra
    Kamalinejad, Mohammad
    Haghdoost, Ali Akbar
    COMPLEMENTARY THERAPIES IN MEDICINE, 2015, 23 (06) : 767 - 772
  • [6] Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease
    Wienrich, M
    Ceci, A
    Ensinger, HA
    Gaida, W
    Mendla, KD
    Osugi, T
    Raschig, A
    Weiser, T
    DRUG DEVELOPMENT RESEARCH, 2002, 56 (03) : 321 - 334
  • [7] A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
    Jones, RW
    Soininen, H
    Hager, K
    Aarsland, D
    Passmore, P
    Murthy, A
    Zhang, R
    Bahra, R
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (01) : 58 - 67
  • [8] Adding memantine to therapy with rivastigmine in patients with mild to moderate Alzheimer's disease: Results of a 12-week pilot study
    Riepe, MW
    Adler, G
    Ibach, B
    Tracik, F
    NEUROLOGY, 2005, 64 (06) : A363 - A364
  • [9] Memantine and Functional Communication in Alzheimer's Disease: Results of a 12-Week, International, Randomized Clinical Trial
    Saxton, Judith
    Hofbauer, Robert K.
    Woodward, Michael
    Gilchrist, Nigel L.
    Potocnik, Felix
    Hsu, Hai-An
    Miller, Michael L.
    Pejovic, Vojislav
    Graham, Stephen M.
    Perhach, James L.
    JOURNAL OF ALZHEIMERS DISEASE, 2012, 28 (01) : 109 - 118
  • [10] Effects of memantine on functional communication in moderate Alzheimer's disease: results of a 12-week placebo-controlled trial
    Graham, S.
    Saxton, J.
    Woodward, M.
    Gilchrist, N.
    Potocnik, F.
    Hofbauer, R. K.
    Yu, S. Y.
    Hsu, H.
    Perhach, J. L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S624 - S624
12345